Leerink Partners Initiates Coverage On NervGen Pharma with Outperform Rating, Announces Price Target of $10

Leerink Partners analyst Marc Goodman initiates coverage on NervGen Pharma (NASDAQ:NGEN) with a Outperform rating and announces Price Target of $10.